A.R.T. Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

A.R.T. Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,116	Closed	-$86K	–	1564
2017 Q1	$86K	Buy	+11,116	New	+$83.5K	﹤0.01%	1285
2016 Q3	–	Sell	-1,935	Closed	-$17K	–	899
2016 Q2	$17K	Buy	+1,935	New	+$22.4K	﹤0.01%	1308
2015 Q4	–	Sell	-928	Closed	-$46K	–	1593
2015 Q3	$46K	Buy	+928	New	+$79.1K	﹤0.01%	1298

Other funds holding KALV

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

A.R.T. Advisors's KALV Position: Q2 2017 in Review

A.R.T. Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2017, closing a stake of 11,116 shares — an estimated $86K sold.

A.R.T. Advisors first reported a position in KALV in Q3 2015 and held it in 3 quarters. The position peaked at $86K in Q1 2017. 18 funds tracked by Wall St. Rank hold KALV as of Q2 2017.

A.R.T. Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
A.R.T. Advisors sold 11,116 KalVista Pharmaceuticals shares in Q2 2017, an estimated $86K.
A.R.T. Advisors first reported a position in KalVista Pharmaceuticals in Q3 2015 and held it in 3 quarters.
A.R.T. Advisors's KalVista Pharmaceuticals position peaked at $86K in Q1 2017.
18 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2017.

Based on A.R.T. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.